A human antibody against pathologic IAPP aggregates protects beta cells in type 2 diabetes models

Fabian Wirth, Fabrice D. Heitz, Christine Seeger, Ioana Combaluzier, Karin Breu, Heather C. Denroche, Julien Thevenet, Melania Osto, Paolo Arosio, Julie Kerr-Conte, C. Bruce Verchere, François Pattou, Thomas A. Lutz, Marc Y. Donath, Christoph Hock, Roger M. Nitsch and Jan Grimm ()
Additional contact information
Fabian Wirth: Neurimmune AG
Fabrice D. Heitz: Neurimmune AG
Christine Seeger: Neurimmune AG
Ioana Combaluzier: Neurimmune AG
Karin Breu: Neurimmune AG
Heather C. Denroche: University of British Columbia
Julien Thevenet: Univ-Lille, Inserm, CHU Lille
Melania Osto: Vetsuisse Faculty of the University of Zürich
Paolo Arosio: ETH Zürich
Julie Kerr-Conte: Univ-Lille, Inserm, CHU Lille
C. Bruce Verchere: University of British Columbia
François Pattou: Univ-Lille, Inserm, CHU Lille
Thomas A. Lutz: Vetsuisse Faculty of the University of Zürich
Marc Y. Donath: University Hospital Basel
Christoph Hock: Neurimmune AG
Roger M. Nitsch: Neurimmune AG
Jan Grimm: Neurimmune AG

Nature Communications, 2023, vol. 14, issue 1, 1-15

Abstract: Abstract In patients with type 2 diabetes, pancreatic beta cells progressively degenerate and gradually lose their ability to produce insulin and regulate blood glucose. Beta cell dysfunction and loss is associated with an accumulation of aggregated forms of islet amyloid polypeptide (IAPP) consisting of soluble prefibrillar IAPP oligomers as well as insoluble IAPP fibrils in pancreatic islets. Here, we describe a human monoclonal antibody selectively targeting IAPP oligomers and neutralizing IAPP aggregate toxicity by preventing membrane disruption and apoptosis in vitro. Antibody treatment in male rats and mice transgenic for human IAPP, and human islet-engrafted mouse models of type 2 diabetes triggers clearance of IAPP oligomers resulting in beta cell protection and improved glucose control. These results provide new evidence for the pathological role of IAPP oligomers and suggest that antibody-mediated removal of IAPP oligomers could be a pharmaceutical strategy to support beta cell function in type 2 diabetes.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-41986-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-41986-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-41986-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().